Drug Trial Radar · NCT01742299
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Mar 26, 2013
Primary completion
Apr 20, 2026
Study completion Apr 20, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 5, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue benefiting from treatment.
Conditions
- GIST and CML
Interventions
imatinib mesylateDrug
Imatinib was administered orally at a total daily dose ranging from 100 to 800 milligrams. The starting dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment. Imatinib was supplied as 100 milligram and 400 milligram tablets and was administered once daily or, for patients receiving 800 milligrams daily, as 400 milligrams twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)
Locations
29 sites in 11 countries. Site status is shown where the registry gives one.
University of California LA
Los Angeles, California
Northwestern University
Chicago, Illinois
Sidney Kimmel CCC At JH
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Weill Cornell Medical Center
New York, New York
Oregon Health Sciences University
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Poitiers, France
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Bucharest, Romania
Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Basel, Switzerland
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Ankara, Sihhiye Altindag, Turkey (Türkiye)
Novartis Investigative Site
Manchester, United Kingdom
Novartis Investigative Site
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.